Indication: This study is developed to evaluate the efficacy of Xxxx compared to placebo
for the treatment of agitation associated with Alzheimer’s disease.
Frequency of Visit: Screening Visit: 1 In Person Visit: 6
STUDY CRITERIA
Age: 65 to 90 years old
Gender: Both
STUDY DETAILS
Study Number: 006
Study Requirement: *Diagnosis of probable Alzheimer's disease *Clinically significant agitation, at the time of screening and for at least 2 weeks prior to
baseline
Stipend: Compensation provided to both Subject and Informant